

Nicola Coppola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/429578/publications.pdf>

Version: 2024-02-01

244
papers

7,043
citations

66234

42
h-index

95083

68
g-index

249
all docs

249
docs citations

249
times ranked

7784
citing authors

#	ARTICLE	IF	CITATIONS
1	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	1.8	341
2	Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?. <i>Diabetes Care</i> , 2020, 43, 1408-1415.	4.3	341
3	Hepatitis B virus burden in developing countries. <i>World Journal of Gastroenterology</i> , 2015, 21, 11941.	1.4	220
4	Virologic and Clinical Expressions of Reciprocal Inhibitory Effect of Hepatitis B, C, and Delta Viruses in Patients With Chronic Hepatitis. <i>Hepatology</i> , 2000, 32, 1106-1110.	3.6	199
5	Epidemiological and etiological variations in hepatocellular carcinoma. <i>Infection</i> , 2020, 48, 7-17.	2.3	133
6	Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 172-180.	3.7	132
7	HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. <i>Hepatology</i> , 2002, 36, 1285-1291.	3.6	122
8	CV genotype and "silent" HBV coinfection: Two main risk factors for a more severe liver disease. <i>Journal of Medical Virology</i> , 2001, 64, 350-355.	2.5	109
9	Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. <i>Diabetes and Metabolism</i> , 2020, 46, 403-405.	1.4	105
10	Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. <i>Aids</i> , 2006, 20, 1253-1260.	1.0	103
11	The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. <i>Journal of Medical Virology</i> , 2005, 75, 522-527.	2.5	102
12	Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. <i>World Journal of Gastroenterology</i> , 2014, 20, 7635.	1.4	96
13	HBV superinfection in HCV chronic carriers: A disease that is frequently severe but associated with the eradication of HCV. <i>Hepatology</i> , 2009, 49, 1090-1097.	3.6	94
14	Hepatitis B virus and hepatitis C virus infection in healthcare workers. <i>World Journal of Hepatology</i> , 2016, 8, 273.	0.8	82
15	Influence of Chronic Coinfection with Hepatitis B and C Virus on Liver Histology. <i>Infection</i> , 2004, 32, 144-148.	2.3	81
16	Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 160-165.	2.2	75
17	Hyperglycaemia on admission to hospital and COVID-19. <i>Diabetologia</i> , 2020, 63, 2486-2487.	2.9	72
18	Liver microRNA hsa-miR-125a-5p in HBV Chronic Infection: Correlation with HBV Replication and Disease Progression. <i>PLoS ONE</i> , 2013, 8, e65336.	1.1	72

#	ARTICLE	IF	CITATIONS
19	Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. <i>Digestive and Liver Disease</i> , 2012, 44, 49-54.	0.4	71
20	<p>Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2657-2665.	1.1	70
21	Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. <i>Eurosurveillance</i> , 2015, 20, 30009.	3.9	70
22	Clinical significance of hepatitis B surface antigen mutants. <i>World Journal of Hepatology</i> , 2015, 7, 2729.	0.8	69
23	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantationâ€”a position paper. <i>Clinical Microbiology and Infection</i> , 2017, 23, 935-940.	2.8	69
24	Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 735-740.	1.1	68
25	Anticoagulant treatment in COVID-19: a narrative review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 642-648.	1.0	68
26	Clinical Presentation of COVID-19: Case Series and Review of the Literature. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5062.	1.2	65
27	Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. <i>Journal of Medical Virology</i> , 2011, 83, 1909-1916.	2.5	64
28	Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: A multicenter study. <i>Journal of Medical Virology</i> , 2008, 80, 1547-1553.	2.5	63
29	Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. <i>World Journal of Hepatology</i> , 2015, 7, 2323.	0.8	62
30	Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features. <i>Infectious Diseases of Poverty</i> , 2017, 6, 33.	1.5	53
31	Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. <i>World Journal of Hepatology</i> , 2014, 6, 384.	0.8	51
32	<sc>TM</sc>6<sc>SF</sc>2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of <sc>PNPLA</sc>3 polymorphism. <i>Liver International</i> , 2015, 35, 1959-1963.	1.9	51
33	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , 2019, 17, 292.	1.8	49
34	Hepatitis C virus superinfection in hepatitis B virus chronic carriers: A reciprocal viral interaction and a variable clinical course. <i>Journal of Clinical Virology</i> , 2006, 35, 317-320.	1.6	48
35	Clinical Presentation, Outcome, and Response to Therapy Among Patients With Acute Exacerbation of Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1174-1180.e11.	2.4	47
36	Abdominal fat interacts with <sc>PNPLA</sc>3 I148M, but not with the <sc>APOC</sc>3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 517-523.	1.0	47

#	ARTICLE	IF	CITATIONS
37	Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity "LINA) Tj ETQq1 1 0.784314 rgt / Overlock 10	1.4	46
38	Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study. <i>Oncotarget</i> , 2016, 7, 62706-62714.	0.8	46
39	Efficacy of pegylated interferon λ -2a and λ -2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. <i>BMC Infectious Diseases</i> , 2012, 12, 357.	1.3	45
40	Impact of comorbidities on the severity of chronic hepatitis B at presentation. <i>World Journal of Gastroenterology</i> , 2012, 18, 1616.	1.4	44
41	Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 334-340.	2.4	44
42	Vaccination against hepatitis b virus: are Italian medical students sufficiently protected after the public vaccination programme?. <i>Journal of Occupational Medicine and Toxicology</i> , 2015, 10, 41.	0.9	44
43	Burden, risk assessment, surveillance and management of SARS-CoV-2 infection in health workers: a scoping review. <i>Infectious Diseases of Poverty</i> , 2020, 9, 139.	1.5	44
44	A structural equation model to examine the clinical features of mild-to-moderate COVID-19: A multicenter Italian study. <i>Journal of Medical Virology</i> , 2021, 93, 983-994.	2.5	44
45	Hepatitis B virus infection in immigrant populations. <i>World Journal of Hepatology</i> , 2015, 7, 2955.	0.8	43
46	HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 620-628.	1.9	43
47	Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. <i>Journal of Clinical Virology</i> , 2009, 46, 222-229.	1.6	42
48	Rituximab-Based Treatment, HCV Replication, and Hepatic Flares. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-5.	3.3	42
49	Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection. <i>Biochemical and Biophysical Research Communications</i> , 2014, 449, 141-145.	1.0	42
50	Epidemiology and management of hepatitis C virus infections in immigrant populations. <i>Infectious Diseases of Poverty</i> , 2019, 8, 17.	1.5	42
51	Anti-HCV IgG avidity index in acute hepatitis C. <i>Journal of Clinical Virology</i> , 2007, 40, 110-115.	1.6	40
52	Role of occult hepatitis B virus infection in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 11931.	1.4	40
53	Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. <i>Neurological Sciences</i> , 2021, 42, 3523-3526.	0.9	40
54	Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. <i>Infection</i> , 2013, 41, 225-229.	2.3	39

#	ARTICLE	IF	CITATIONS
55	The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. <i>BMC Infectious Diseases</i> , 2015, 15, 149.	1.3	39
56	Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A. <i>Current Medicinal Chemistry</i> , 2014, 21, 1391-1404.	1.2	39
57	Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 559-567.	1.3	38
58	Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. <i>Virology Journal</i> , 2015, 12, 186.	1.4	38
59	Olfactory loss and brain connectivity after COVID-19. <i>Human Brain Mapping</i> , 2022, 43, 1548-1560.	1.9	38
60	HAV replication in acute hepatitis with typical and atypical clinical course. <i>Journal of Medical Virology</i> , 2003, 71, 1-6.	2.5	37
61	Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016, 213, 1897-1905.	1.9	37
62	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1a-4 in Italy. <i>Scientific Reports</i> , 2018, 8, 8988.	1.6	36
63	Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. <i>Journal of Medical Virology</i> , 2001, 65, 681-687.	2.5	34
64	Absence of occult hepatitis C virus infection in patients under immunosuppressive therapy for oncohematological diseases. <i>Hepatology</i> , 2011, 54, 1487-1489.	3.6	34
65	Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey. <i>Digestive and Liver Disease</i> , 2016, 48, 1066-1071.	0.4	34
66	Age and Gender Distribution of Hepatitis C Virus Genotypes in the Metropolitan Area of Naples. <i>Intervirology</i> , 2013, 56, 206-212.	1.2	33
67	Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. <i>BMC Infectious Diseases</i> , 2018, 18, 251.	1.3	33
68	Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors. <i>PLoS ONE</i> , 2014, 9, e94542.	1.1	33
69	Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf. <i>Oncotarget</i> , 2017, 8, 25289-25299.	0.8	33
70	Virological Pattern in Plasma, Peripheral Blood Mononuclear Cells and Liver Tissue and Clinical Outcome in Chronic Hepatitis B and C virus Coinfection. <i>Antiviral Therapy</i> , 2008, 13, 307-318.	0.6	33
71	Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. <i>Journal of Hepatology</i> , 2005, 42, 646-651.	1.8	32
72	Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 20-26.	0.6	32

#	ARTICLE	IF	CITATIONS
73	Acute Hepatitis with Severe Cholestasis and Prolonged Clinical Course Due to Hepatitis A Virus Ia and Ib Coinfection. <i>Clinical Infectious Diseases</i> , 2007, 44, e73-e77.	2.9	31
74	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	1.9	31
75	Clinical and Virological Improvement of Hepatitis B Virus-Related or Hepatitis C Virus-Related Chronic Hepatitis with Concomitant Hepatitis A Virus Infection. <i>Clinical Infectious Diseases</i> , 2006, 42, 1536-1543.	2.9	30
76	Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. <i>Journal of Viral Hepatitis</i> , 2009, 17, 493-500.	1.0	30
77	HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. <i>Journal of Clinical Virology</i> , 2013, 58, 315-317.	1.6	30
78	Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease. <i>Medicine (United States)</i> , 2016, 95, e4311.	0.4	30
79	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 493.	0.9	29
80	An update on the treatment options for HBV/HCV coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1691-1702.	0.9	29
81	Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1211-1223.	1.9	28
82	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018, 68, 597-600.	1.8	28
83	Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. <i>Journal of Medical Virology</i> , 2007, 79, 1679-1685.	2.5	27
84	Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. <i>World Journal of Gastroenterology</i> , 2019, 25, 3299-3312.	1.4	27
85	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. <i>Journal of Infection</i> , 2013, 67, 322-328.	1.7	26
86	Acute Hepatitis B and C Virus Coinfection: A Virological and Clinical Study of 3 Cases. <i>Clinical Infectious Diseases</i> , 2003, 36, 528-532.	2.9	25
87	A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2013, 13, e8352.	0.1	25
88	The effect of an antimicrobial stewardship programme in two intensive care units of a teaching hospital: an interrupted time series analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 782.e1-782.e6.	2.8	25
89	Distribution Pattern of Hepatitis C Virus Genotypes and Correlation with Viral Load and Risk Factors in Chronic Positive Patients. <i>Intervirology</i> , 2014, 57, 311-318.	1.2	24
90	Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 2188-2194.	1.2	24

#	ARTICLE	IF	CITATIONS
91	Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV mono-infection. <i>Infection</i> , 2013, 41, 959-967.	2.3	23
92	Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1337-1349.	0.9	23
93	Clinical and virological characteristics associated with severe acute hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014, 20, O991-O997.	2.8	23
94	Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. <i>Journal of Medical Virology</i> , 2016, 88, 1659-1671.	2.5	23
95	Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018, 10, 558-570.	0.8	23
96	Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. <i>World Journal of Gastroenterology</i> , 2015, 21, 10749.	1.4	23
97	Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy. <i>Infection</i> , 2018, 46, 93-101.	2.3	22
98	Management of SARS-CoV-2 pneumonia. <i>Journal of Medical Virology</i> , 2021, 93, 1276-1287.	2.5	22
99	Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. <i>World Journal of Virology</i> , 2015, 4, 1.	1.3	22
100	Absence of occult HCV infection in patients experiencing an immunodepression condition. <i>Infezioni in Medicina</i> , 2013, 21, 296-301.	0.7	22
101	Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). <i>Viruses</i> , 2019, 11, 850.	1.5	21
102	Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. <i>Journal of Nephrology</i> , 2019, 32, 763-773.	0.9	21
103	Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium. <i>Journal of Viral Hepatitis</i> , 2020, 27, 941-947.	1.0	21
104	Renal Involvement in COVID-19: A Review of the Literature. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 895-903.	1.1	21
105	More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 662746.	1.3	21
106	Dementia as Risk Factor for Severe Coronavirus Disease 2019: A Case-Control Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 698184.	1.7	21
107	Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103724.	0.9	21
108	Molecular epidemiology of hepatitis B virus genotypes circulating in acute hepatitis B patients in the Campania region. <i>Journal of Medical Virology</i> , 2014, 86, 1683-1693.	2.5	20

#	ARTICLE	IF	CITATIONS
109	Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy. <i>Annals of Hepatology</i> , 2018, 17, 47-53.	0.6	20
110	Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. <i>Infection</i> , 2018, 46, 761-783.	2.3	20
111	Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. <i>Infection</i> , 2014, 42, 601-610.	2.3	19
112	HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. <i>Life</i> , 2021, 11, 169.	1.1	19
113	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1123-1130.	1.4	18
114	Antibiotic resistance in diabetic foot infection: how it changed with COVID-19 pandemic in a tertiary care center. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108797.	1.1	18
115	Role of genetic polymorphisms in hepatitis C virus chronic infection. <i>World Journal of Clinical Cases</i> , 2015, 3, 807.	0.3	18
116	Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. <i>New Microbiologica</i> , 2018, 41, 26-29.	0.1	18
117	Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study*. <i>Journal of Viral Hepatitis</i> , 2006, 13, 67-71.	1.0	17
118	Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti-“Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1800-1802.	2.4	17
119	Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 830-837.	2.8	17
120	Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient. <i>Journal of Infection</i> , 2020, 81, 979-997.	1.7	16
121	The impact of viral molecular diversity on the clinical presentation and outcome of acute hepatitis B in Italy. <i>New Microbiologica</i> , 2015, 38, 137-47.	0.1	16
122	Absence of <i>Helicobacter</i> spp in the liver of patients with primary or metastatic liver cancer. <i>Hepatology</i> , 2002, 36, 1300-1301.	3.6	15
123	Tolerability and efficacy of anti-“HBV nucleos(t)ide analogues in HBV“DNA“positive cirrhotic patients with HBV/HCV dual infection. <i>Journal of Viral Hepatitis</i> , 2012, 19, 890-896.	1.0	15
124	Prevalence of latent tuberculosis infection and associated risk factors among 3,374 healthcare students in Italy. <i>Journal of Occupational Medicine and Toxicology</i> , 2014, 9, 34.	0.9	15
125	Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C. <i>Clinical Microbiology and Infection</i> , 2016, 22, 372-378.	2.8	15
126	Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection. <i>World Journal of Gastroenterology</i> , 2014, 20, 6707.	1.4	15

#	ARTICLE	IF	CITATIONS
127	The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. Saudi Journal of Gastroenterology, 2018, 24, 25.	0.5	15
128	Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis. Journal of Medical Virology, 2005, 75, 222-226.	2.5	14
129	Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. Journal of Clinical Virology, 2013, 58, 748-750.	1.6	14
130	Hepatitis A virus strains circulating during 1997-2015 in Campania, a Southern Italy region with periodic outbreaks. Journal of Medical Virology, 2017, 89, 1931-1936.	2.5	14
131	Virological patterns of HCV patients with failure to interferon-free regimens. Journal of Medical Virology, 2018, 90, 942-950.	2.5	14
132	An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: A meta-analysis. Journal of Viral Hepatitis, 2020, 27, 415-427.	1.0	14
133	Innovative procedures for micro-elimination of HCV infection in persons who use drugs. Journal of Viral Hepatitis, 2020, 27, 1437-1443.	1.0	14
134	Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. World Journal of Hepatology, 2014, 6, 677.	0.8	14
135	Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World Journal of Hepatology, 2015, 7, 2510.	0.8	14
136	Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study. Journal of Medical Virology, 2017, 89, 2138-2143.	2.5	13
137	Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. Journal of Viral Hepatitis, 2018, 25, 198-204.	1.0	13
138	The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. Digestive and Liver Disease, 2019, 51, 434-437.	0.4	13
139	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. Journal of Antimicrobial Chemotherapy, 2020, 75, 3349-3358.	1.3	13
140	Cannabinoid Receptor 2-63 QQ Variant Is Associated with Persistently Normal Aminotransferase Serum Levels in Chronic Hepatitis C. PLoS ONE, 2014, 9, e99450.	1.1	13
141	Prognostic Value of Transaminases and Bilirubin Levels at Admission to Hospital on Disease Progression and Mortality in Patients with COVID-19: An Observational Retrospective Study. Pathogens, 2022, 11, 652.	1.2	13
142	ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens. Antiviral Therapy, 2017, 22, 551-558.	0.6	12
143	Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2021, 27, 28-35.	2.8	12
144	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3a-infected patients within the Italian network VIRONET. Liver International, 2021, 41, 1802-1814.	1.9	12

#	ARTICLE	IF	CITATIONS
145	Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic. <i>World Journal of Gastroenterology</i> , 2021, 27, 7271-7284.	1.4	12
146	Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. <i>Antiviral Therapy</i> , 2008, 13, 307-18.	0.6	12
147	Long-term outcome of hepatitis B and hepatitis C virus coinfection and single HBV infection acquired in youth. <i>Journal of Medical Virology</i> , 2009, 81, 2012-2020.	2.5	11
148	Liver Histology in HIV/Hepatitis C-Coinfected and HCV-Monoinfected Patients With Persistently Normal Alanine Aminotransferases. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 107-108.	0.9	11
149	Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection. <i>Antiviral Therapy</i> , 2012, 17, 1453-1458.	0.6	11
150	Prevalence and associated risk factors of latent tuberculosis infection among undergraduate and postgraduate dental students: A retrospective study. <i>Archives of Environmental and Occupational Health</i> , 2017, 72, 99-105.	0.7	11
151	Molecular diversity in irregular or refugee immigrant patients with HBV genotype infection living in the metropolitan area of Naples. <i>Journal of Medical Virology</i> , 2017, 89, 1015-1024.	2.5	11
152	HBV molecular epidemiology and clinical condition of immigrants living in Italy. <i>Infection</i> , 2018, 46, 523-531.	2.3	11
153	Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. <i>Annals of Hepatology</i> , 2013, 13, 20-6.	0.6	11
154	GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1179-1186.	2.0	10
155	Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfecting patients. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 164-169.	0.3	10
156	Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3005-3010.	1.1	10
157	Prevalence of latent tuberculosis infection in healthcare workers at a hospital in Naples, Italy, a low-incidence country. <i>Journal of Occupational Medicine and Toxicology</i> , 2016, 11, 53.	0.9	10
158	Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfecting patients. <i>PLoS ONE</i> , 2017, 12, e0181890.	1.1	10
159	Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 607-614.	1.3	10
160	Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7144.	1.2	10
161	Is liver biopsy necessary for hepatitis C virus carriers with persistently normal aminotransferase levels?. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 831-833.	0.8	9
162	Lipodystrophy and serum lipid abnormalities in HIV-positive sub-Saharan population on ART. <i>Journal of Infection</i> , 2006, 53, e29-e33.	1.7	9

#	ARTICLE	IF	CITATIONS
163	Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT). <i>Infection</i> , 2014, 42, 811-815.	2.3	9
164	Management of HBV reactivation in non-oncological patients. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 611-624.	2.0	9
165	Correlation Between the Hepatic Expression of Human MicroRNA hsa-miR-125a-5p and the Progression of Fibrosis in Patients With Overt and Occult HBV Infection. <i>Frontiers in Immunology</i> , 2018, 9, 1334.	2.2	9
166	HDV infection in immigrant populations. <i>Journal of Medical Virology</i> , 2019, 91, 2049-2058.	2.5	9
167	A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 846-855.	1.0	9
168	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , 2019, 39, 484-493.	1.9	9
169	Blood-borne chronic viral infections in a large cohort of immigrants in southern Italy: A seven-centre, prospective, screening study. <i>Travel Medicine and Infectious Disease</i> , 2020, 35, 101551.	1.5	9
170	TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. <i>World Journal of Gastroenterology</i> , 2016, 22, 8509.	1.4	9
171	The Impact of the SARS-Cov2 Pandemic on a Persuasive Educational Antimicrobial Stewardship Program in a University Hospital in Southern Italy: A Pre-Post Study. <i>Antibiotics</i> , 2021, 10, 1405.	1.5	9
172	Dermoscopy of dermatofibrosarcoma protuberans on black skin. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, e119-e120.	0.6	8
173	CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. <i>Digestive and Liver Disease</i> , 2016, 48, 1364-1369.	0.4	8
174	Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 676-681.	0.8	8
175	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	2.0	8
176	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro. <i>Viruses</i> , 2020, 12, 251.	1.5	8
177	Prevalence of occult HBV infection in Western countries. <i>Journal of Medical Virology</i> , 2020, 92, 2917-2929.	2.5	8
178	Delirium and Cognitive Impairment as Predisposing Factors of COVID-19 Infection in Neuropsychiatric Patients: A Narrative Review. <i>Medicina (Lithuania)</i> , 2021, 57, 1244.	0.8	8
179	Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab. <i>Neurological Sciences</i> , 2022, 43, 2947-2949.	0.9	8
180	Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project. <i>Journal of Infection and Public Health</i> , 2022, 15, 562-565.	1.9	8

#	ARTICLE	IF	CITATIONS
181	Virological and Epitope Evolution of HCV Infection from Acute Hepatitis C to Subsequent Episodes of HCV-Related Acute Liver Cell Necrosis. <i>Infection</i> , 2009, 37, 344-348.	2.3	7
182	The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2015, 21, 609.e1-609.e4.	2.8	7
183	Low prevalence of HTLV1/2 infection in a population of immigrants living in southern Italy. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006601.	1.3	7
184	Cardiovascular System in COVID-19: Simply a Viewer or a Leading Actor?. <i>Life</i> , 2020, 10, 165.	1.1	7
185	Impact of an Education-Based Antimicrobial Stewardship Program on the Appropriateness of Antibiotic Prescribing: Results of a Multicenter Observational Study. <i>Antibiotics</i> , 2021, 10, 314.	1.5	7
186	SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis. <i>Infection</i> , 2022, 50, 849-858.	2.3	7
187	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic? Standardized National Screening or One Tailored to Local Epidemiology?. <i>Biology</i> , 2022, 11, 609.	1.3	7
188	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. <i>Life</i> , 2020, 10, 146.	1.1	6
189	Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence. <i>Medicine (United States)</i> , 2020, 99, e18948.	0.4	6
190	Inappropriateness of Antibiotic Prescribing in Medical, Surgical and Intensive Care Units: Results of a Multicentre Observational Study. <i>Life</i> , 2021, 11, 475.	1.1	6
191	Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. <i>Life</i> , 2021, 11, 17.	1.1	6
192	<i>Helicobacter</i> spp. and liver diseases. <i>Infezioni in Medicina</i> , 2003, 11, 201-7.	0.7	6
193	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. <i>Scientific Reports</i> , 2022, 12, 5736.	1.6	6
194	A Phase II Study on the Effect of Taurisolo® Administered via AEROSol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study. <i>Cells</i> , 2022, 11, 1499.	1.8	6
195	Clinical Expression of 'Silent' Hepatitis B Virus Infection in a Patient with Visceral Leishmaniasis. <i>Infection</i> , 2001, 29, 166-169.	2.3	5
196	The Reactivation of Occult HBV Infection Emerging with the Case of Acute Hepatitis B in the Wife of a Subject Treated with Rituximab-Based Chemotherapy. <i>Antiviral Therapy</i> , 2015, 20, 349-352.	0.6	5
197	Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. <i>Clinical Microbiology and Infection</i> , 2017, 23, 777.e1-777.e4.	2.8	5
198	Suture thread check test for detection of surgical site contamination: a prospective study. <i>Journal of Surgical Research</i> , 2017, 220, 268-274.	0.8	5

#	ARTICLE	IF	CITATIONS
199	Geographical pattern of chronic liver diseases in Italy: Results from two pooled national surveys. <i>European Journal of Internal Medicine</i> , 2019, 61, 40-43.	1.0	5
200	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. <i>Antiviral Therapy</i> , 2019, 24, 485-493.	0.6	5
201	Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis. <i>Acta Biomedica</i> , 2019, 90, 187-196.	0.2	5
202	Hepatitis B Virus Genotypes, Epidemiological Characteristics, and Clinical Presentation of HBV Chronic Infection in Immigrant Populations Living in Southern Italy. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	5
203	Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 5201.	1.0	5
204	ÂTreatment of chronic HBV infection in developing countries. <i>Annals of Hepatology</i> , 2016, 15, 816-823.	0.6	5
205	Antiviral treatment of HCV-related cirrhosis. <i>Digestive and Liver Disease</i> , 2007, 39, S96-S101.	0.4	4
206	HCV Genotype-3h, a Difficult-to-Diagnose Sub-Genotype in the DAA Era. <i>Antiviral Therapy</i> , 2018, 23, 605-609.	0.6	4
207	<i>In vivo</i> evidence that the cannabinoid receptor 2â€™63 <sc>RR</sc> variant is associated with the acquisition and/or expansion of <sc>HIV</sc> infection. <i>HIV Medicine</i> , 2018, 19, 597-604.	1.0	4
208	HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. <i>Viruses</i> , 2018, 10, 363.	1.5	4
209	Hepatitis C late relapse in patients with directly acting antiviralâ€™related sustained virological response at week 12. <i>Liver International</i> , 2019, 39, 844-853.	1.9	4
210	Perioperative Antibiotic Prophylaxis: Knowledge and Attitudes among Resident Physicians in Italy. <i>Antibiotics</i> , 2020, 9, 357.	1.5	4
211	Screening for infectious diseases in newly arrived asymptomatic immigrants in southern Italy. <i>Eastern Mediterranean Health Journal</i> , 2019, 25, 246-253.	0.3	4
212	DAA-Based Treatment for HIVâ€™HCV-Coinfected Patients: Analysis of Factors of Sustained Virological Response in a Real-Life Study. <i>Antiviral Therapy</i> , 2020, 25, 193-201.	0.6	4
213	Meetâ€™Testâ€™Treat for HCV management: patientsâ€™ and cliniciansâ€™ preferences in hospital and drug addiction services in Italy. <i>BMC Infectious Diseases</i> , 2022, 22, 3.	1.3	4
214	Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5199-5208.	1.1	4
215	Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review. <i>Journal of Chemotherapy</i> , 2022, 34, 360-366.	0.7	4
216	Epidemiological, Clinical and Microbiological Characteristics of Patients with Bloodstream Infections Due to Carbapenem-Resistant K.ÂPneumoniae in Southern Italy: A Multicentre Study. <i>Antibiotics</i> , 2022, 11, 633.	1.5	4

#	ARTICLE	IF	CITATIONS
217	Is liver biopsy necessary for hepatitis C virus carriers with persistently normal aminotransferase levels?. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 831-833.	0.8	3
218	PNPLA3 I148M variant as a risk factor for carotid atherosclerosis in chronic hepatitis C. <i>International Journal of Cardiology</i> , 2014, 172, 291-292.	0.8	3
219	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multicentre study and systematic review. <i>Journal of Viral Hepatitis</i> , 2018, 25, 920-929.	1.0	3
220	Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1323, 115-147.	0.8	3
221	Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106067.	1.1	3
222	Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. <i>Viruses</i> , 2021, 13, 432.	1.5	3
223	Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy. <i>Life</i> , 2021, 11, 347.	1.1	3
224	Efficacy of Unsupervised Self-Collected Mid-Turbinate FLOQSwabs for the Diagnosis of Coronavirus Disease 2019 (COVID-19). <i>Viruses</i> , 2021, 13, 1663.	1.5	3
225	Synchronous and metachronous gastric glist with pancreatic adenocarcinoma: report of 2 cases and a review of literature. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2015, 8, 298-301.	0.6	3
226	Prevalence and Therapeutic Management of Infections by Multi-Drug-Resistant Organisms (MDROs) in Patients with Liver Cirrhosis: A Narrative Review. <i>Antibiotics</i> , 2022, 11, 232.	1.5	3
227	Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. <i>Infezioni in Medicina</i> , 2015, 23, 134-9.	0.7	3
228	Absence of occult HCV infection in HIV-positive patients. <i>Journal of Infection</i> , 2012, 64, 436-437.	1.7	2
229	Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. <i>Liver Cancer International</i> , 2020, 1, 12-24.	0.2	2
230	Assessment and Comparison of Two Serological Approaches for the Surveillance of Health Workers Exposed to SARS-CoV-2. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4501-4507.	1.1	2
231	Clinical characterization of gingival type of burning mouth syndrome: a cross-sectional study. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2021, 26, e802-e807.	0.7	2
232	No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis. <i>Infezioni in Medicina</i> , 2018, 26, 244-248.	0.7	2
233	Acute kidney injury in COVID-19: a case-report. <i>International Urology and Nephrology</i> , 2020, 52, 2213-2214.	0.6	1
234	The Role of Bacterial Colonization of the Suture Thread in Early Identification and Targeted Antibiotic Treatment of Surgical Site Infections: A Prospective Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4416.	1.2	1

#	ARTICLE	IF	CITATIONS
235	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life "Liver Network Activity"™ (LINA) cohort update results. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1057-1063.	1.4	1
236	HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. <i>Biomedicines</i> , 2021, 9, 1352.	1.4	1
237	Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease. <i>Vaccines</i> , 2022, 10, 298.	2.1	1
238	Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis. <i>PLoS ONE</i> , 2022, 17, e0265178.	1.1	1
239	Delirium and Psychiatric Sequelae Associated to SARS-CoV-2 in Asymptomatic Patients With Psychiatric History and Mild Cognitive Impairment as Risk Factors: Three Case Reports. <i>Frontiers in Psychiatry</i> , 2022, 13, 868286.	1.3	1
240	Blood donor serological screening for SARS-CoV-2 as a tool to estimate the prevalence of asymptomatic infection in a low-intermediate endemic area of southern Italy after the first wave of the pandemic. <i>Blood Transfusion</i> , 2021, , .	0.3	1
241	Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report. <i>Vaccines</i> , 2022, 10, 1021.	2.1	1
242	Virus Variability and Its Impact on HIV and Hepatitis Therapy. <i>Advances in Virology</i> , 2012, 2012, 1-3.	0.5	0
243	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , 2015, 14, 325-32.	0.6	0
244	Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant. <i>Infezioni in Medicina</i> , 2015, 23, 285-7.	0.7	0